LENSAR, Inc. (NASDAQ: LNSR) announced that it has reached an agreement with Alcon Research, LLC to terminate their merger agreement.
LENSAR and Alcon agreed that ending the merger agreement is in the best interest of both companies, as the necessary U.S. regulatory approvals are unlikely to be obtained by the original deadline of April 23, 2026, or the extended deadline of July 23, 2026.
LENSAR will keep the $10.0 million deposit specified in the merger agreement.
Nick Curtis, President and CEO of LENSAR, stated, “While we are disappointed with this outcome and the FTC’s intention to challenge the proposed transaction, we remain committed to advancing the field of cataract surgery through the continued market growth of our ALLY Robotic Cataract Laser System™.”
 and Alcon Research, LLC have mutually agreed to terminate their merger agreement due to anticipated difficulties in obtaining required U.S.){kind=link}